NICHD spermicide trial receives FDA advisory committee endorsement.
This article was originally published in The Tan Sheet
Executive Summary
NICHD SPERMICIDE TRIAL ENDORSED BY FDA ADVISORY COMMITTEES at a Nov. 22 joint meeting of FDA's Nonprescription Drugs, Reproductive Health Drugs, Anti-Infective Drugs and Antiviral Drugs Advisory Committees in Gaithersburg, Md. The joint committee overwhelmingly agreed that more efficacy data is needed for marketed OTC vaginal spermicides and lauded the National Institute of Child Health & Human Development's proposed four-year, 1,200-subject study of several marketed nonoxynol-9-containing vaginal spermicides as a source of much-needed information on efficacy in pregnancy prevention.